"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

"A Prospective, Randomized, Double-blind, Placebo Controlled and Comparative Clinical Study Evaluating Scar-management Modalities for Simple and Effective Management of Hyperproliferative (Hypertrophic) Scars and Keloids"

A Phase II prospective, randomized, double-blind, placebo controlled and comparative clinical study evaluating hydrogel scar-management modalities for effective management of hyperproliferative scars and keloids.

This is a double-blinded study, which means that neither the evaluating physician nor the subject will know which treatment is administered.

Group selection and assignment will be made at random, with a 2 in 5 chance of receiving a market-approved therapy, and 1 in 5 chance of receiving the placebo. Subjects assigned the placebo-moisturizer will receive a standard hypoallergenic dermatological hydrating cream base. Subjects assigned the silicone gel, will receive a commercially available, active comparator.

Study Overview

• Status: Completed
• Conditions: Cicatrix; Scar; Keloid; Hypertrophic Scar
• Intervention / Treatment: Other: Placebo Cream Base Emulsion Moisturizer; Other: FS2 Emulsion Moisturizer; Other: Active Comparator Onion Skin Extract Gel (Mederma); Other: Active Comparator Silicone Gel (Kelo-Cote); Other: Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer

Detailed Description

A Phase II prospective, randomized, double-blind, placebo controlled and comparative clinical study evaluating hydrogel scar-management modalities for effective management of hyperproliferative scars and keloids. Unlike raised and, or hyperproliferative scars that result from aberrant wound healing, keloids are the result of inherited genetic mutations in a variety of proteins essential to orchestrated wound repair. Whereas hyperproliferative scars may have shared similar abnormalities throughout the repair of a primary injury, they are not predictors of subsequent scarring following scar revision. Keloids on the other hand will return upon excision, and in some cases larger in size than the excised scar tissue. Current treatment options for keloids as well as hypertrophic scars include intralesional corticosteroids, silicone gel sheeting, compression, surgery and adjuvants to surgery, including radiation and cryotherapy.

Onion skin extract, silicone, and a variety of over-the-counter selfcare product options are available for patients with keloids and hypertrophic scars. Despite market approval, robust efficacy data to substantiate product claims is scarce. At best, comparative studies have been able to demonstrate significance between modalities/products. With only a limited number of investigator initiated studies with scar-patients the advancement in this niche, yet expansive, medical sector has been incremental across decades of research. This study is being undertaken to investigate the efficacy and safety of a FS2- moisturizer, and two market-approved scar topical therapies. The FS2- moisturizer is claimed to be substantially equivalent or superior to market approved Onion skin extract (Mederma), and silicone gel (Kelo-Cote)intended to manage and improve hyperproliferative closed scars. The study builds upon a recent study that investigated safety and efficacy of a petrolatum lotion vs. onion-extract gel vs. placebo in subjects with hypertrophic scars and keloids. There two (2) Study Arms and five (5) Treatment Groups. Treatment Groups consist of: placebo moisturizer cream base, Onion skin extract (Mederma), FS2-moisturizer formulations, silicone gel (Kelo-Cote), and an FS2-silicone gel.

This is a double-blinded study, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study team member will administer the treatment, as well as answer questions and discuss any problems prior to starting, and for the duration of, the study.

Subjects will be assigned a Treatment Group from those listed above. Group selection and assignment will be made at random, with a 2 in 5 chance of receiving a market-approved therapy, and 1 in 5 chance of receiving the placebo. Subjects assigned the placebo-moisturizer will receive a standard hypoallergenic dermatological hydrating cream base. Subjects assigned the silicone gel, will receive a commercially available, active comparator.

• Study Type: Interventional
• Enrollment (Actual): 75
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Florida
    • Aventura, Florida, United States, 33180
      • The Center for Clinical and Cosmetic Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female
2. Adult, Senior (>18 years of age)
3. Healthy or medically stable
4. Keloid or hypertrophic scar
5. Willing and able to follow study requirements
6. Etiology and clinical assessment of the scar indicate that it could benefit from the study treatments

Exclusion Criteria:

1. Subjects who are medically unstable
2. Subjects who are expected to be medically unstable for the duration of the study period and an additional 1-month thereafter
3. Pregnant subjects, or those attempting to become pregnant
4. Subjects with known immunosuppression or immunosuppressive illness
5. Subjects with uncontrolled diabetes or autoimmune disorders
6. Subjects with known sensitivity to ingredients in the test-treatment products
7. Subjects who are enrolled in another scar study and/or plan to receive or are receiving scar treatments other than study treatment during the trial period
8. Subjects who have received scar treatment, including any investigational treatment, within one month of the first day of study treatment
9. Subjects with any skin conditions or taking any medications that may interfere with the study medication
10. Subjects who had any clinical evidence of severe ongoing or prolonged depression, mental illness, and/or who has demonstrated evidence of drug abuse
11. Any other diagnosis, condition, physical or geographical limitation that may render, or increases the likelihood of rendering, the Subject unable to complete the entire study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FS2 Emulsion Moisturizer; The FS2 Emulsion Moisturizer Arm is comprised of three (3) topical treatments including: Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer and Active Comparator Onion Skin Extract Gel (Mederma). The topical treatments are applied b.d. for 120 days.	Other: Placebo Cream Base Emulsion Moisturizer; Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days; Other: FS2 Emulsion Moisturizer; Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days; Other: Active Comparator Onion Skin Extract Gel (Mederma); Topical onion skin extract gel (Mederma) applied b.d. for 120 days
Experimental: Active Comparator + FS2 Emulsion Moisturizer; The Active Comparator + FS2 Emulsion Moisturizer Arm is comprised of two (2) topical treatments including: Active Comparator Silicone Gel (Kelo-Cote), and Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer. The topical treatments are applied b.d. for 120 days.	Other: Active Comparator Silicone Gel (Kelo-Cote); Topical silicone gel (Kelo-Cote) applied b.d. for 120 days; Other: Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer; Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Vancouver Scar Scale (VSS)	Investigator assessment of target scar or keloid using the Vancouver Scar Scale (VSS). Scale parameters include: Pigmentation (0-2), Vascularity (0-3), Pliability (0-5), and Height (0-3). Scale measurements include: minimum score of 0 = normal to a maximum score of 2, 3 or 5 depending on the parameter measured.	180 Days
Patient and Observer Scar Assessment Scale (POSAS)	Investigator assessment of target scar or keloid using the Patient and Observer Scar Assessment Scale (POSAS). Scale parameters include: Vascularity, Pigmentation, Thickness, Relief, Pliability, and Surface Area. Scale measurements include: minimum score of 1 = normal skin to a maximum score of 10 = worst scar imaginable.	180 Days

Collaborators and Investigators

• Sponsor: The Center for Clinical and Cosmetic Research
• Collaborators: BirchBioMed Inc.
• Investigators: Principal Investigator: Mark S Nestor, M.D., Ph.D., The Center for Clinical and Cosmetic Research

Publications and helpful links

Helpful Links

• BirchBioMed Inc.
• Mederma
• Kelo-Cote

Study record dates

Study Major Dates

• Study Start (Actual): February 7, 2019
• Primary Completion (Actual): September 4, 2020
• Study Completion (Actual): November 3, 2020

Study Registration Dates

• First Submitted: November 15, 2019
• First Submitted That Met QC Criteria: November 18, 2019
• First Posted (Actual): November 20, 2019

Study Record Updates

• Last Update Posted (Actual): March 21, 2022
• Last Update Submitted That Met QC Criteria: March 7, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Scar; Keloid; Hypertrophic Scar; Cicatrix
• Additional Relevant MeSH Terms: Pathologic Processes; Connective Tissue Diseases; Pathological Conditions, Anatomical; Fibrosis; Collagen Diseases; Hypertrophy; Cicatrix; Keloid; Cicatrix, Hypertrophic
• Other Study ID Numbers: CCCR 02-2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No